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For decades, the scientific community has been perplexed about the incongruent relationship between blood cholesterol concentrations and risk of coronary heart disease (CHD). This conflict stems from observational evidence indicating that both plasma LDL-cholesterol (LDL-C) levels and plasma HDL-cholesterol (HDL-C) levels are strongly associated with the risk of CHD. Whereas the path to show the causal role of LDL-C in CHD has been smooth, with orthogonally targeted pharmaceutical agents (statins, ezetimibe, and PCSK9 inhibitors) providing consistent evidence in randomized clinical trials (RCTs), the path has been more tortuous for drugs targeting HDL-C. Questions on the statistical robustness of the association between HDL-C and risk of CHD were raised 25 years ago 1 . Accordingly, investi gators have sought to clarify the role of HDL-C in cardiovascular diseases with the use of genetic studies, the most recent example being the findings reported by Ference et al. in 2017 , and interventional clin ical trials, with the latest findings coming from the REVEAL trial 6 show that use of plasma LDL-C levels as a marker of drug efficacy might lead to an exaggerated estimation of the clinical benefit of CETP inhibition when combined with statin treatment, as opposed to use of plasma APOB levels, similar to findings from REVEAL 2 .
The first phase III RCT of a CETP inhibitor (ILLUMINATE 7 ) showed that torcetrapib raised plasma HDL-C levels by 72% and lowered plasma LDL-C levels by 25% compared with placebo in patients at high risk of cardio vascular disease (n = 15,067). However, the trial was terminated early owing to a 25% higher risk of major vascular events in the torcetrapib group, linked to elevated systolic blood pressure (SBP) 7 . Of note, an associ ation between CETP inhib ition and high SBP was identified for all CETP inhibitors tested in phase III RCTs. In the dal-OUTCOMES trial 8 , which included 15,871 patients with a recent acute coronary syndrome, the CETP inhibitor dalce trapib increased HDL-C levels by 31-40% from baseline, but had a minimal effect on LDL-C levels. This trial was terminated early owing to futility, with a hazard ratio (HR) for the primary end point of major vascular events of 1.04 (95% CI 0.93-1.16). In the subsequent ACCELERATE trial , evacetrapib, an efficacious CETP inhibitor, increased HDL-C levels by 132% and lowered LDL-C levels by 37% compared with placebo in patients with established vascular disease (n = 12,092), but ACCELERATE was terminated after a median of 26 months of treatment owing to futility, with a HR for the primary end point of major vascular events of 1.01 (95% CI 0.91-1.11). In 2017, and as a surprise to the cardiovascular community, the REVEAL trial 2 demonstrated a beneficial effect of anacetrapib, another potent CETP inhibitor. Compared with placebo, anacetrapib treatment led to a 104% increase in plasma HDL-C levels and a 17% or 41% reduction in LDL-C levels (measured by β-quantification or direct method, respectively), and after a median of 4.1 years of treatment, yielded a HR of 0.91 (95% CI 0.85-0.97) for major coro nary events in patients with prior vascular disease (n = 30,449).
How do we explain the seemingly conflicting findings from the multiple trials of CETP inhibitors and the genetic studies of HDL-C and CETP? First, the REVEAL 2 findings do as summarized in REF. 3 . Nevertheless, subsequent studies using more-contemporary MR approaches (which take into account genetic pleiotropy) and larger sets of singlenucleotide poly morphisms (SNPs) identified in HDL-C genome-wide association studies (GWAS) have also shown a neutral association between plasma HDL-C levels and risk of CHD 4 . These findings led to the prevailing interpretation that plasma HDL-C levels are unlikely to have an important role in the aetiology of CHD.
Genetic studies of a biomarker (such as HDL-C levels) are distinct from those of a drug target, because drug targets tend not to show specificity for the exposure of interest. Cholesteryl ester transfer protein (CETP) facili tates transport of cholesterol from HDL particles to particles containing apolipoprotein B (APOB), such as very low-density lipoproteins, in exchange for triglycerides. Therefore, one way of elevating HDL-C levels is through therapeutic inhibition of CETP. Indeed, potent CETP inhibitors lead to an elevation of plasma HDL-C levels and a reduction in Friedewald-measured LDL-C levels. Early genetic studies provided weak evidence showing that CETP genetic variants were linked to the risk of CHD; however, subsequent, large-scale evidence provides robust associations, including the identification of a CETP variant associated with CHD (P = 9.8 × 10 −9 ) in a hypothesis-free GWAS published in 2017 (REF. 5 ). Furthermore, in a DY S L I P I DA E M I A
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Initial randomized trials of cholesteryl ester transfer protein (CETP) inhibitors were terminated early owing to adverse effects or futility. The REVEAL trial now shows the benefit of CETP inhibition in coronary heart disease. Despite raising HDL-cholesterol levels, the cardiovascular effect of CETP inhibitors is probably due to lowering of non-HDL-cholesterol levels.
not change the notion that circulating HDL-C levels are unlikely to have an important role in the aetiology of CHD: CETP inhibitors that did not have a large effect on the levels of atherogenic lipoproteins, as measured by LDL-C or APOB, showed no association with CHD 8 . Second, the magnitude of effect on non-HDL-C levels and the corresponding risk of CHD reported in REVEAL are entirely consistent with those reported in trials of statins, ezeti mibe, and PCSK9 inhibitors (FIG. 1) ; the genetic associations that correspond to these drug targets scaled to the same difference in non-HDL-C line up on a steeper slope, a result that is expected given that the effect of atherogenic lipoproteins on the risk of cardio vascular disease accumulates over a lifetime. Third, the neutral finding in ACCELERATE 9 with evacetrapib -a drug that had a similar lipid profile to anacetrapib in REVEAL 2 , including strong non-HDL-C lowering -is likely to arise from the premature termin ation of the trial: in REVEAL, the HR for major coronary events at 2 years of follow-up was 0.96 (95% CI 0.84-1.10) 2 , which overlaps with the estimation for major vascular events in ACCELERATE 9 . Furthermore, in REVEAL, the HR for major coronary events after 4.1 years was stronger than for major vascular events (HR 0.93, 95% CI 0.88-0.99), indicating that the composite primary outcome in ACCELERATE might have included end points that attenuated the association. Moving forward, crucial questions include the mechanisms underlying the increase in SBP seen with CETP inhibition (with the exception of the disproportionate effect seen with torcetrapib, the modest SBP increase seen with CETP inhibitors seems to be correlated with the degree of increase in HDL-C levels and might therefore be target-mediated); whether therapeutic CETP inhibition leads to age-related macular degeneration, as predicted by genetic studies 10 (which REVEAL was underpowered to detect); whether CETP inhibitors alter the risk of diabetes mellitus (a modest beneficial effect was seen in both REVEAL and ACCELERATE); which patients might derive clinical benefit from CETP inhib itors; and the cost-efficiency of CETP inhibitor treatment. Certainly, the findings from REVEAL bring to a close the long-standing discordance between findings from MR studies (which anticipated cardiovascular benefit from therapeutic inhibition of CETP) and phase III RCTs (which, before REVEAL 2 , corresponding showed no such benefit). For lipidoligists, the accumulating data point towards a unifying theory of APOB driving CHD, and, for HDL, it might be back to the drawing board.
